Professors Fuhr and Blackstone, both senior fellows at ACI, published an article on biologic drugs for the Center for Biosimilars. The article is available online.
Biologics
The Maine Wire: Congress Should Preserve Public Quality Standards for Biologic Drugs
Congress should preserve public quality standards for biologic drugs
Biosimilars: The Grand Experiment
Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]
Coalition Letter Calling on the Senate Not to End the Current Development of Quality Standards for Biologics
July 23, 2019 Dear Chairman Grassley and Ranking Member Wyden, As organizations representing American consumers, seniors, taxpayers, and free-market advocates, we are writing to express concerns over Section 207 of S. 1895, the Lower Health Care Costs Act. Many provisions of the bill would expand consumer choice, save taxpayer money, and lower out-of-pocket costs for […]
Regulatory Uncertainty and Industry Practices Force Consumers to Overpay on Biologics
Biopharmaceuticals are preparations synthesized from living organisms, especially a human or animal protein, such as a hormone or antitoxin that is used as a diagnostic, preventive, or therapeutic agent. If the preparation is the original drug, it can be patented. Most of us have seen TV adverts for patented new wonder drugs such as Humira, […]
Forbes: Biosimilar Competition Will Lower Consumer Prices
When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight, and Valeant Pharmaceuticals International raised a blood pressure drug price by nearly 3,000 percent since 2013, among other consumer losing examples. […]
Prescription Drug Competition Means Savings
REAL CLEAR POLICY: Competition for some of the priciest drugs may soon be coming to a pharmacy near you. The new development has to do with “biologics,” which are drugs produced in living systems such as plant and animal cells or microorganisms. To Continue Reading, visit Real Clear Policy
Video on Biosimilar Competition
ACI’s Capitol Hill event, held of December 9, 2014, discussed the importance of speeding market entry to permit biosimilar competition. That competition would give consumers increased access to lower priced medicine, which would lead to better patient outcomes. Watch the event of the event.
ACI in Forbes: FDA Action Can Save Lives, Money
Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but the FDA needs to write the rules necessary to permit competitive entry. His piece is available to read and print at Forbes.
ACI in the Huffington Post: FDA Delays Will Cost Money and Lives
This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs. These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics. Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients. The article calls on the FDA to accelerate its rulemaking and write […]